Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fabien Tillier
Observed name:
F. Tillier
Institution:
Eurofins (United States)
Observed institutions:
Eurofins (United States),
Eurofins (France)
ORCID:
0000-0001-5137-7834
Observed ORCID:
0000-0001-5137-7834
OpenAlex ID:
A5013085804
Safety screening in early drug discovery: An optimized assay panel
2019
·
Stefanie Bendels
, Caterina Bissantz
, et al.
·
Journal of Pharmacological and Toxicological Methods
·
87
Can we discover pharmacological promiscuity early in the drug discovery process?
2012
·
Jens-Uwe Peters
, Jérôme Hert
, et al.
·
Drug Discovery Today
·
87
BioPrint Meets the AI Age: Development of Artificial Intelligence-Based ADMET Models for the Drug-Discovery Platform SAFIRE
2024
·
Sarah E Biehn
, Luis Miguel Goncalves
, et al.
·
Future Medicinal Chemistry
·
10
The determination of epigenetic target specificity and identification of epigenetics-related in vivo adverse drug reactions
2013
·
Annie Otto-Bruc
, Boryeu Mao
, et al.
·
Journal of Pharmacological and Toxicological Methods
·
1
OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target Liabilities
2026
·
Sarah E. Biehn
, Juerg Lehmann
, et al.
·
Pharmaceuticals
PDF
Enhanced interpretation of secondary pharmacology data through automated visualization tools to support safety assessment
2025
·
Emilie Desfosses
, Samuel Ramirez
, et al.
·
Journal of Pharmacological and Toxicological Methods
LP-44 Enhanced interpretation of secondary pharmacology data through automated visualization tools to support safety assessment
2024
·
E. Desfosses
, S. Ramirez
, et al.
·
Toxicology Letters
Show more works
View as search
Works count:
7
Citation count:
185
H-index:
3
I10-index:
3
Year
Topic
Type
